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Hesperetin,aselectivephosphodiesterase(PDE)4inhibitor,ispresentinthetraditionalChinesemedicine,“ChenPi.”Therefore,we
were interested in investigating its eﬀects on ovalbumin- (OVA-) induced airway hyperresponsiveness, and clarifying its rationale
for ameliorating asthma and chronic obstructive pulmonary disease (COPD). Hesperetin was revealed to have a therapeutic
(PDE4H/PDE4L)ratioof>11.Hesperetin(10∼30μmol/kg,intraperitoneally(i.p.))dose-dependentlyandsigniﬁcantlyattenuated
the airway hyperresponsiveness induced by methacholine. It also signiﬁcantly suppressed the increases in total inﬂammatory
cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of cytokines, including interleukin (IL)-2, IL-4, IL-5,
interferon-γ,andtumornecrosisfactor-αinbronchoalveolarlavageﬂuid(BALF).Itdose-dependentlyandsigniﬁcantlysuppressed
totalandOVA-speciﬁcimmunoglobulinElevelsintheBALFandserum.However,hesperetindidnotinﬂuencexylazine/ketamine-
induced anesthesia, suggesting that hesperetin has few or no emetic eﬀects. In conclusion, the rationales for ameliorating allergic
asthma and COPD by hesperetin are anti-inﬂammation, immunoregulation, and bronchodilation.
1.Introduction
Phosphodiesterases (PDEs) are classiﬁed according to their
primary protein and complementary (c)DNA sequences,
cofactors, substrate speciﬁcities, and pharmacological roles.
It is now known that PDEs comprise at least 11 dis-
tinct enzyme families that hydrolyze adenosine 3 ,5  cyclic
monophosphate (cAMP) and/or guanosine 3 ,5  cyclic
monophosphate (cGMP) [1]. PDE1∼5 isozymes, which are
calcium/calmodulin dependent (PDE1), cGMP stimulated
(PDE2), cGMP inhibited (PDE3), cAMP speciﬁc (PDE4),
and cGMP speciﬁc (PDE5), were found to be present in the
canine trachea [2], guinea pig lungs [3], and human bronchi
[4]. PDE3 and PDE4 were identiﬁed in the guinea pig airway
[5], but other isozymes might also be present. PDE4 may
adopttwodiﬀerentconformationswhichhavehigh(PDE4H)
and low (PDE4L)a ﬃnities for rolipram, respectively. In
general, it is believed that inhibition of PDE4H is associated
with adverse responses, such as nausea, vomiting, and gastric
hypersecretion, while inhibition of PDE4L is associated with
anti-inﬂammatory and bronchodilating eﬀects. Therefore
the therapeutic ratio of selective PDE4 inhibitors for use in
treating asthma and chronic obstructive pulmonary disease
(COPD) is deﬁned as the PDE4H/PDE4L ratio [6, 7].
Hesperetin (5,7,3 -trihydroxy-4 -methoxyﬂavanone,
molwt., 302.28), one of the most common ﬂavonoids in
Citrus, is also present in herbal medicine as glycosides. For
example, hesperidin and neohesperidin are abundantly2 Evidence-Based Complementary and Alternative Medicine
p r e s e n ti nt h ef r u i tp e e lo fCitrus aurantium L. (Rutaceae),
a well-known traditional Chinese medicine (TCM) called
“Chen-Pi”; they are used as an expectorant and stomach
tonic, and contain vitamin P, a remedy for preventing
capillary fragility and hypertension [8]. These glycosides
are easily hydrolyzed by glycosidase to form hesperetin after
ingestion. Men with higher hesperetin intake have lower
mortality from cerebrovascular disease and lung cancer,
and lower incidences of asthma [9]. Because hesperetin was
reported to selectively inhibit PDE4 activity [10], and to
inhibit the maturation and function of monocyte-derived
dendritic cells from patients with asthma [11]. Therefore,
we were interested in investigating the PDE4H/PDE4L ratio
and suppressive eﬀects of hesperetin on ovalbumin- (OVA-)
induced airway hyperresponsiveness (AHR), and clarifying
its rationale for ameliorating asthma and COPD.
2.MaterialsandMethods
2.1. Reagents and Animals. Hesperetin, OVA, methacholine
(MCh), aluminum sulfate hexadecahydrate, dimethylsulfox-
ide (DMSO), chloralose, urethane, Tris-HCl, Bis-Tris, ben-
zamidine, phenylmethanesulfonyl ﬂuoride (PMSF), d,l-dith-
iothreitol,polyethyleneimine,ethylenediaminetetraaceticac-
id (EDTA), bovine serum albumin (BSA), cAMP, cGMP, cal-
modulin, Dowex resin, Crotalus atrox snake venom, xylazine,
and ketamine were purchased from Sigma Chemical (St.
Louis, MO, USA). Vinpocetine, erythro-9-(2-hydroxy-3-
nonyl)-adenine HCl (EHNA), milrinone, 4-(3-butoxy-4-
methoxybenzyl)-2-imidazolidinone (Ro 20-1724), and za-
prinast were purchased from Biomol (Plymouth Meeting,
PA,USA).Freund’sadjuvant(Mycobacteriumbutyricum)was
purchased from Pierce Biotechnology (Rockford, IL, USA).
Mouse T helper (Th)1/Th2 cytokine CBA kits, and mouse
IgE enzyme-linked immunosorbent assay (ELISA) sets were
purchased from Pharmingen (San Diego, CA, USA). Ethyl
alcohol and polyethylene glycol (PEG) 400 were purchased
from Merck (Darmstadt, Germany). [3H]-cAMP, [3H]-
cGMP, and [methyl- 3H]-rolipram were purchased from
Amersham Pharmacia Biotech (Buckinghamshire, UK).
Other reagents, such as CaCl2,M g C l 2,a n dN a C l ,w e r eo f
analytical grade. Hesperetin, rolipram, and Ro 20-1724 were
dissolved in a mixture of ethyl alcohol and DMSO (1:1).
Other reagents were dissolved in distilled water.
Male Hartley guinea pigs (500∼600g) and female
BABL/c mice at 8∼12 weeks old were purchased from the
Animal Center of the National Science Council (Taipei,
Taiwan), and housed in ordinary cages at 22 ± 1◦Cw i t ha
humidity of 50% ∼60% under a constant 12/12-h light/dark
cycle and provided with food and water ad libitum.U n d e ra
protocolapprovedbytheAnimalCareandUseCommitteeof
Taipei Medical University, the following in vivo experiments
were performed.
2.2. Competitive Inhibition of PDE4 Activity by Hesperetin.
Activity of PDE4 in the homogenate of guinea pig lungs or
hearts was measured by a two-step procedure according to
the previous method [12], using cAMP with [3H]-cAMP as
s u b s t r a t e .T h ee n z y m ep r e p a r a t i o n( 2 5 μL) was incubated
for 30min at 37◦C in a total assay volume of 100μLc o n -
taining 50mM Tris-HCl (pH 7.4), 3mM MgCl2,1 m M
dithiothreitol, 0.05% BSA, and 1μMc A M Pw i t h0 . 2 μCi
[3H]-cAMP as a substrate alone. In the Lineweaver-Burk
analysis, the reaction mixture contained 10μLo fv e h i c l e
or inhibitors, at various concentrations of hesperetin or
rolipram, a selective PDE4 inhibitor [13] as a reference drug,
respectively. The reagents and homogenate were mixed on
ice,andthereactionwasinitiatedbytransferringthemixture
to a water bath at 37◦C. Following a 30min incubation, the
reaction was stopped by transferring the reaction vessel to a
bath of boiling water for 3min. After cooling on ice, 20μLo f
a1mg/mLsol u tio no fCrotalusatrox snak ev eno mwasadd ed
to the reaction mixture, and the mixture was incubated at
37◦C for 10min. Unreacted [3H]-cAMP was removed by
the addition of 500μL of a 1-in-1 Tris-HCl (40mM) buﬀer
suspension of Dowex resin (1 × 8-200) with incubation on
ice for 30min. Each tube was then centrifuged at 3700g for
2min, and 150μL of the supernatant was removed for liquid
scintillation counting. Less than 10% of the tritiated cyclic
nucleotide was hydrolyzed in this assay. The total protein
in each fraction used was assayed according to the previous
method [14]. PDE activity is reported as nmol/mg/min.
2.3. Determination of PDE4H Values. When the above-
mentionedguineapigsweresacriﬁced,thewholebrainswere
removed and homogenized with a glass/Teﬂon homogenizer
(Glas-Col, Terre Haute, IN, USA) in 10 volumes of cold
medium (pH 6.5) containing 20mM Bis-Tris, 2mM ben-
zamidine, 2mM EDTA, 50mM sodium chloride, 0.1mM
PMSF, and 1mM dithiothreitol. At 4◦C, the homogenate
was centrifuged at 170g for 5min to remove connective
tissues and blood vessels. The suspended homogenate was
then recentrifuged at 40,000g for 30min to separate the
cytosolic and particulate portions. The particulate portion
was resuspended in a suspension at a concentration of
400mg/mL (wet weight/volume), after washing 3 times
with homogenizing buﬀer. The particulate portion mainly
consisted of cell membranes. The binding ability of hes-
peretin (3∼300μM) on high-aﬃnity rolipram-binding sites
(HARBSs) of membranes was determined by replacing 2nM
[3H]-rolipram in a reaction buﬀer at 30◦C for 1h, according
to the method described by previous investigators [13, 15]
and modiﬁed by us. Brieﬂy, the reaction buﬀer consisted
of 50mM Tris-HCl and 5mM MgCl2 (pH 7.5). The total
volumeofthereactionmixturewas25μL,consistingof10μL
of the particulate suspension, 10μLo f[ 3H]-rolipram, and
5μL of hesperetin or reference drugs, such as rolipram (0.1∼
1,000nM) and Ro 20-1724 (1∼10,000nM) [16]. After 1h,
the reaction was terminated by moving the reaction vessel
into crushed ice. Then the reaction mixture was transferred
onto Whatman GF/B glass-ﬁber ﬁlters, which were soaked
in a 0.3% polyethyleneimine solution in a minifunnel. The
reaction mixture was ﬁltered by centrifugation at 90g for
10s, and the ﬁltrate was collected into a 1.5mL Eppendorf
tube with the top adapted to the outlet of the minifunnel.
The ﬁlters were washed with 300μLo fr e a c t i o nb u ﬀer three
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of cocktail for radiation counting (total binding) using
a β-scintillation counter (Beckman, Fullerton, CA, USA).
Nonspeciﬁc binding, which was deﬁned in the presence of
10μM Ro 20-1724, was subtracted from total binding to
yield speciﬁc binding. Eﬀective concentration (EC50)v a l u e s
of hesperetin, rolipram, and Ro 20-1724, at which a half
of the [3H]-rolipram that was bound onto HARBSs of cell
membranes was displaced, were deﬁned as PDE4H values,
and these were related to any adverse eﬀects, such as nausea,
vomiting, and hypergastric secretion [7].
2.4. Airway Hyperresponsiveness (AHR). In vivo,t e nf e m a l e
BABL/c mice in each group were sensitized by an intraperi-
toneal (i.p.) injection of 20μg of OVA emulsiﬁed in 2.25mg
of an aluminum hydroxide gel, prepared from aluminum
sulfate hexadecahydrate, in a total volume of 100μLo nd a y s
0 and 14. On day 21, these mice were injected with (i.p.)
100μL of a mixture of 1% OVA and Freund’s complete
adjuvant (1:1). Mice were challenged via the airway using
1% OVA in saline for 30min on days 28, 29, and 30
by ultrasonic nebulization. After the last of the primary
OVA challenges [17], AHR was assessed on day 32 (48h
after 1% OVA provocation) in each group. Each group of
mice was administered (i.p.) the vehicle (control) or 3∼
30μmol/kg of hesperetin 2h before and 6 and 24h after
OVA provocation. For comparison, sham-treated mice were
sensitized but challenged with saline instead of 1% OVA
(nonchallenged). The vehicle, a mixture of DMSO:ethyl
alcohol:PEG 400:saline (0.5:0.5:14.5:14.5, v/v), or hes-
peretin was administered (i.p.) at a volume of 0.01mL/g
of body weight. AHR was assessed in unrestrained animals
by barometric plethysmography [18] using a whole-body
plethysmograph (WBP) and analyzed using software of
Life Science Suite P3 Analysis Modules (Gould, LDS Test
and Measurement LLC, Valley View, OH, USA). Mice
were placed into the main chamber of the WBP, and
the baseline enhanced pause (Penh) value was determined.
Then mice were ﬁrst nebulized with phosphate-buﬀered
saline (PBS), and subsequently with increasing doses (6.25∼
50mg/mL) of MCh for 3min for each nebulization, followed
by readings of breathing parameters for 3min after each
nebulization to determine Penh values. Twenty-four hours
after Penh determination, these mice were anesthetized with
pentobarbital(50mg/kg,i.p.),andthelungswerelavagedvia
at r a c h e a lt u b ew i t hP B S( 1× 1.0mL, 37 ◦C). After lavage,
blood was collected from the jugular vein and allowed to
sit so that it would coagulate. The collected bronchoalveolar
lavage ﬂuid (BALF) and coagulated blood were, respectively,
centrifuged at 630g for 7min and at 3700g for 10min at
4◦C. After centrifugation, the BALF and serum supernatants
were stored at −20◦C until determination of cytokines,
including interleukin (IL)-2, IL-4, IL-5, tumor necrosis
factor (TNF)-α, and interferon (IFN)-γ by ﬂow cytometric
methods [19] using mouse T helper (Th)1/Th2 cytokine
CBA kits, and of total immunoglobulin (Ig)E using ELISA
kits (Pharmingen, San Diego, CA, USA) according to the
respective recommendations of the manufacturers. OVA-
speciﬁc IgE was measured as described previously [20]. Wells
were coated with 100μLo fO V A( 2 0μg/mL) instead of the
capture antibody. Levels are expressed in arbitrary units,
where 1 arbitrary unit equals the optical density of the
sample divided by the optical density of unchallenged mouse
serumorBALF(standard).TheBALFpelletwasresuspended
in ACK lysing buﬀer (1.658g NH4Cl, 0.2g KHCO3,a n d
1.44mg EDTA in 200mL of water) to lyse the residual
erythrocytes in each sample. The number of inﬂammatory
cellswascountedusingahemocytometer(HausserScientiﬁc,
Horsham, PA, USA). Cytospun slides were stained and
diﬀerentiated in a blinded fashion by counting at least 100
cells under light microscopy.
2.5. Xylazine/Ketamine-Induced Anesthesia. According to a
previously described method [21] and modiﬁed by us,
hesperetin (10∼100μmol/kg, subcutaneously (s.c.)) or Ro
20-1724 (0.01∼1μmol/kg, s.c.), a reference drug, was,
respectively, injected into 8∼12-week-old female BALB/c
mice 1 or 0.25h prior to an i.p. injection of xylazine
(10mg/kg)/ketamine (70mg/kg). The vehicle (control) for
hesperetin or Ro 20-1724 was a mixture of DMSO:ethyl
alcohol:PEG 400:saline (0.5:0.5:14.5:14.5, v/v). After loss
of the righting reﬂex (i.e., when a mouse remained on its
back and no longer spontaneously righted itself to a prone
position), the duration of anesthesia was measured until its
return as the endpoint [21].
2.6. Statistical Analysis. All values are given as the mean ±
SEM. Diﬀerences among values were statistically calculated
by one-way analysis of variance (ANOVA), and then deter-
mined by Dunnett’s test. The diﬀerence between two values,
however,wasdeterminedbyStudent’st-test.Diﬀerenceswith
P<0.05 were considered statistically signiﬁcant.
3. Results
3.1. Competitive Inhibition of PDE4 Activity by Hesperetin.
According to the Lineweaver-Burk analysis, hesperetin (10∼
100μM) and rolipram (1∼10μM) competitively inhibited
PDE4 activity (Figure 1), because 1/Vmax values were not
signiﬁcantly aﬀected by various concentrations of hesperetin
(a) or rolipram (b). Their Ki values were, respectively,
calculated to be 45.6 ± 2.3( n = 4) and 3.6 ± 1.8( n = 5) μM
(Figure 1 inset).
3.2. PDE4H Values. Rolipram (0.1∼1,000nM) and Ro 20-
1724 (1∼10,000nM), concentration-dependently and eﬀec-
tively displaced 2nM [3H]-rolipram binding on HARBSs
of guinea pig brain cell membranes (Figure 2). However,
hesperetin even at 300μM displaced those only by 17.5 ±
9.5%(n = 4)(Figure 2).Ther especti v eEC 50 (PDE4H)values
of rolipram, Ro 20-1724, and hesperetin for displacing [3H]-
roliprambindingwere7.5±3.4(n = 4)nM,45.6±9.7(n = 4)
nM, and >300μM.
3.3. Supsression of Airway Hyperresponsiveness In Vivo . Penh
values at the baseline for the control (vehicle), nonchal-
lenged, and 3, 10, and 30μmol/kg hesperetin groups were4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Inhibition of PDE4 induced cAMP hydrolysis by hesperetin (a) and rolipram (b). Activities of PDE4 in the presence of various
concentrationsofhesperetinorrolipram,andthesubstrate(cAMP)wereplottedaccordingtoaLineweaver-Burkanalysis.Ki wasdetermined
from the equation of the apparent Km as a function of the inhibitor concentration (inset). Each value represents the mean ± SEM. The
experimental number for hesperetin, and rolipram was 4 and 5, respectively.
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Figure 2: Displacement of [3H]-rolipram by rolipram, Ro 20-1724,
and hesperetin in high-aﬃnity rolipram binding sites of guinea
pig brain particulate. Each value represents the mean ± SEM. The
experimental number for each was 4.
2.37 ± 0.04, 2.40 ± 0.05, 2.42 ± 0.03, 2.35 ± 0.05, and
2.42±0.04,respectively,andthesevaluesdidnotsigniﬁcantly
diﬀer from each other. Penh values with PBS nebulization
for each group were 2.42 ± 0.05, 2.43 ± 0.03, 2.38 ± 0.05,
2.36 ± 0.04, and 2.44 ± 0.05, respectively, which also did
not signiﬁcantly diﬀer from each other. Administration
of nebulized PBS did not aﬀect the Penh value of the
baseline in each group. However, MCh (6.25∼50mg/mL)
concentration-dependentlyincreasedPenh valuesfrom1-fold
with PBS exposure to 2.93 ± 0.32-fold in control sensitized
and challenged mice (Figure 3(a)). Penh values of MCh at
50mg/mL in control sensitized and challenged mice were
signiﬁcantly enhanced compared to those in non-challenged
mice. Hesperetin (10∼30 μmol/kg, i.p.) dose-dependently
and signiﬁcantly attenuated the enhancement of Penh values
induced by 50mg/mL MCh (Figure 3(a)).
3.4. Suppression of Inﬂammatory Cells in BALF. Total
inﬂammatory cells, macrophages, lymphocytes, neutrophils,
and eosinophils from the BALF of control sensitized and
challenged mice signiﬁcantly increased compared to those
of nonchallenged mice (Figure 3(b)). Hesperetin (10∼
30μmol/kg, i.p.) signiﬁcantly suppressed the increases in
total inﬂammatory cells, macrophages, lymphocytes, neu-
trophils, and eosinophils. Hesperetin even at 3μmol/kg (i.p.)
also suppressed the increase of eosinophils (Figure 3(b)).
3.5. Suppression of Cytokines in BALF. Compared to those in
nonchallenged mice, levels of cytokines, such as IL-2, IL-4,
IL-5, IFN-γ,a n dT N F - α, in the BALF of control sensitized
and challenged mice signiﬁcantly increased (Figure 3(c)).
Hesperetin (3 ∼30μmol/kg, i.p.) signiﬁcantly suppressed
increases in levels of IL-2, IL-4, IL-5, IFN-γ,a n dT N F - α
with the exception of IL-5 at doses of 3 and 10μmol/kg
(Figure 3(c)).
3.6. Suppression of IgE in the Serum and BALF. Levels of
total and OVA-speciﬁc IgE in the BALF and serum of controlEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀects of hesperetin (10∼100μmol/kg, i.p.) on the enhanced pause (Penh) (a), inﬂammatory cells (b), and cytokines (c) in sen-
sitized mice which received aerosolized methacholine (6.25∼50mg/mL) 2 days after primary allergen challenge. #P<0.05, ##P<0.01, and
###P<0.001, compared to the nonchallenged group. ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001, compared to the control (vehicle) group.
The number of mice in each group was 10. Total: total cells; Mac: macrophages; Lym: lymphocytes; Neu: neutrophils; Eos: eosinophils; IL:
interleukin; IFN: interferon; TNF: tumor necrosis factor.
sensitized and challenged mice were signiﬁcantly enhanced
compared to those of non-challenged mice. For example,
Hesperetin (10∼30μmol/kg, i.p.) dose-dependently and
signiﬁcantly suppressed these enhancements (Figures 4(a),
4(b), 4(c),a n d4(d)).
3.7. No Eﬀect on Xylazine/Ketamine-Induced Anesthesia.
The durations of xylazine/ketamine-induced anesthesia in
control (vehicle) mice of the Ro 20-1724- and hesperetin-
treated groups were 21.0 ± 2.5( n = 10) and 22.1 ±
2.2min(n = 10),respectively.Ro20-1724(0.01∼1μmol/kg,
s.c.) dose-dependently shortened the duration, and at
doses of 0.1 and 1μmol/kg (s.c.) signiﬁcantly shortened
the duration (Figure 5(a)). In contrast, hesperetin (10∼
100μmol/kg,s.c.)didnotsigniﬁcantlyinﬂuencetheduration
(Figure 5(b)).
4. Discussion
Allergic asthma is a chronic respiratory disease characterized
by AHR, mucus hypersecretion, bronchial inﬂammation,
and elevated IgE levels. Th2 cells, together with other
inﬂammatory cells such as eosinophils, B cells, and mast cells
were proposed as critical to the initiation, development, and
chronicity of this disease [22]. One hypothesis emphasizes
an imbalance in Th cell populations favoring expression
of Th2 over Th1 cells. Cytokines released from Th2 cells
are IL-4, IL-5, IL-6, IL-9, and IL-13, and those from Th1
cells are IL-2, IL-12, IFN-γ,a n dT N F - α [23, 24]. In the
present results, hesperetin (10∼30μmol/kg, i.p.) signiﬁ-
cantly reduced Penh values at 50mg/mL MCh (Figure 3(a))
suggesting that it signiﬁcantly suppresses AHR. All types
of inﬂammatory cells examined, including total inﬂam-
matory cells, macrophages, lymphocytes, neutrophils, and6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀects of hesperetin (3∼30μmol/kg, i.p.) on total IgE (a, c) and ovalbumin-speciﬁc IgE (b, d) levels in bronchial alveolar lavage
ﬂuid (a, b) and serum (c, d) of sensitized mice which had received aerosolized methacholine (6.25∼50mg/mL) 2 days after primary allergen
challenge. #P<0.05, ##P<0.01and ###P<0.001,comparedtothenonchallengedgroup. ∗P<0.05, ∗∗P<0.01and ∗∗∗P<0.001,compared
to the control (vehicle) group. Each value represents the mean ± SEM. The number of mice in each group was 10.
eosinophils in the BALF of sensitized and challenged mice
were reduced (Figure 3(b)). Hesperetin (10∼30μmol/kg,
i.p.) also suppressed levels of IL-2, IL-4, IL-5, IFN-γ,a n d
TNF-α (Figure 3(c)). These results suggest that hesperetin
suppresses both Th1 and Th2 cells which are respectively
implicated in autoimmune and atopic diseases [25].
IL-4 and IL-13 were shown to induce AHR in mouse
asthma models [26, 27]. IL-4 has three primary eﬀects.
First, IL-4 promotes B cell diﬀerentiation to plasma cells
that secrete antigen-speciﬁc IgE antibodies. Second, IL-
4 promotes mast cell proliferation. Third, increased IL-4
upregulatesendothelialcellexpressionofadhesionmolecules
foreosinophils[28].IL-5mobilizesandactivateseosinophils,
leading to the release of a major basic protein, cysteinyl-
leukotriene, and eosinophil peroxidase that contribute to
tissue damage and AHR [27, 29]. Phosphoinositide 3-
kinase δ (p110δ) was shown to play a crucial role in the
development, diﬀerentiation, and antigen receptor-induced
proliferation of mature B cells [30, 31], and inhibition of
p110δ attenuates allergic airway inﬂammation and AHR in
a murine asthma model [30, 32]. In addition, IL-4 and
IL-13 are important in directing B cell growth, diﬀeren-
tiation, and secretion of IgE [33]. In addition, hesperetin
(10∼30μmol/kg, i.p.) dose-dependently and signiﬁcantly
suppressed total and OVA-speciﬁc IgE levels in the BALF
and serum of sensitized and challenged mice, suggesting
that hesperetin has immunoregulatory and antiallergic asth-
matic eﬀects. The results support the recent ﬁnding that
orally administered hesperidin (hesperetin-7-rutinoside or
hesperetin-7-rhamnoglucoside), inhibited inﬂammatory cell
inﬁltration and mucus hypersecretion in a murine model of
asthma [34].
Hesperetin has been reported to selectively inhibit PDE4
activity in our previous report [10], and in the present
results, it was revealed to competitively inhibit PDE4 activity.
Selective PDE4 inhibitors speciﬁcally prevent the hydrolysis
of cAMP, a 3 ,5 -cyclic nucleotide, and therefore have broad
anti-inﬂammatoryeﬀectssuchasinhibitionofcelltraﬃckingEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Eﬀects of subcutaneously administered Ro 20-1724 (a) and hesperetin (b) on the duration of xylazine (10mg/kg, i.p.)/ketamine-
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ATP cAMP AMP cAMP-PDEs
Hesperetin selectively
inhibits PDE4
Activates PKA
Bronchodilation
AC
Total inﬂammatory cells,
macrophages, lymphocytes
Anti-inﬂammation Immunoregulation
Suppresses airway
hyperresponsiveness
cAMP ↑
Ca2+ extrusion ↑
Ca2+ uptake to SR ↑
(Ca2+)i ↓
Total and OVA-speciﬁc IgE ↓
Th2-released IL-4 and IL-5 ↓
Th1-released IL-2, IFN-γ and TNF-α ↓
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Figure 6: Mechanisms of action of hesperetin. Hesperetin selectively inhibits PDE4 activity and results in an increase in cAMP, which
activates cAMP-dependent protein kinase (PKA) and increases calcium extrusion from the intracellular space and uptake to sarcoplasmic
reticula (SR). Therefore, hesperetin largely decreases the concentration of intracellular calcium ([Ca2+]i) and results in bronchodilation. The
increase in cAMP also has anti-inﬂammatory and immunoregulatory eﬀects. AC: adenylate cyclase; Th: T-helper cells; Ig: immunoglobulin;
IL: interleukin; IFN: interferon; TNF: tumor necrosis factor. Up and down arrows, respectively, indicate increases and decreases.
and of cytokine and chemokine release from inﬂammatory
cells. The increased cAMP levels induced by these selective
PDE4 inhibitors subsequently activate cAMP-dependent
protein kinase which may phosphorylate and inhibit myosin
light-chain kinase, thus inhibiting contractions [35]. The
precise mechanism through which relaxation is produced
by this second-messenger pathway is not known, but it
may result from decreased intracellular Ca2+ ([Ca2+]i). The
decrease in [Ca2+]i may be due to reduced inﬂux of Ca2+,
enhanced Ca2+ uptake into the sarcoplasmic reticula, or
enhancedCa2+ extrusionthroughcellmembranes[35].Thus
selective PDE4 inhibitors may have bronchodilatory eﬀects.
The second-generation PDE4 inhibitors, cilomilast and rof-
lumilast,havereachedtheclinicaltrialstageandexhibitsome
beneﬁcial eﬀects in treating asthma and COPD [36]. The
eﬀectivenessofthesePDE4inhibitorsmaybelimitedbytheir
clinical potency when using doses that have minimal adverse
eﬀects such as headaches, diarrhea, nausea, and abdominal
pain. The PDE4H/PDE4L ratios of cilomilast and roﬂumilast
were, respectively, reported to be 117.8nM/120nM (1), and
2.4nM/0.8nM (3) [15, 37], which are considerably greater
than that (0.01∼0.001) of rolipram [7]. Owing to its adverse8 Evidence-Based Complementary and Alternative Medicine
eﬀects or lack of eﬃcacy, cilomilast was discontinued for
use against asthma after phase II clinical trials in 2003
[36]. In terms of tolerability over 6 months with 15mg
twice daily for COPD in a phase III study, cilomilast was
reported to be associated with higher frequencies of diarrhea
and nausea than a placebo [36]. Roﬂumilast was evaluated
for asthma and COPD in phase III clinical trials, and was
reported to reduce those adverse eﬀects after longer-term
treatment at 0.5mg once daily [36]. Roﬂumilast, compared
to a placebo, was reported to signiﬁcantly improve the mean
pre-andpostbronchodilatorforcedexpiratoryvolumesin1s
(FEV1)inpatientswithmoderate-to-severeCOPD.However,
nausea, diarrhea, weight loss, and headaches were more
frequent in patients in the roﬂumilast group. These adverse
events were associated with increased patient withdrawal
[38, 39]. Recently, roﬂumilast was approved by the European
Commission as an add-on to bronchodilator therapy for
maintenance treatment of severe COPD associated with
chronic bronchitis in adults with a history of frequent
exacerbations. However, the US Food and Drug Adminis-
tration voted against using roﬂumilast to treat COPD. The
PDE4H/PDE4L ratio of AWD 12-281, another selective PDE4
inhibitor, was reported to be 104nM/9.7nM (approximately
11) [40]. AWD 12-281 was undergoing clinical development
phase IIa trials for COPD, and was reported to be a
unique potential drug for the topical treatment of asthma
and COPD [41]. AWD 12-281 was reported to be a very
promising drug candidate for treating lung inﬂammation
when administered by inhalation and for treating atopic
dermatitis [42]. However, AWD-12-281 was also discontin-
ued in clinical trials for both asthma and COPD owing to
al a c ko fe ﬃcacy [43, 44]. Many compounds that are in
development will not reach the market as monotherapies
unless their emetic liability is reduced [45], although inhaled
GSK256066 demonstrated eﬃcacy in trials in asthma [46]
and oral apremilast was clinically reported to be eﬀective
fortreating severe plaque-type psoriasis [47].PDE4 subtypes
(A∼D) may be considered for drug development of new
PDE4 inhibitors. PDE4D inhibition in nontarget tissues
promotes emesis, since PDE4D knock-out mice showed
reduction of xylazine/ketamine-triggered anesthesia which is
usedasasurrogatemarkerforemesisinmice,anonvomiting
species [21]. Recently, small-molecule allosteric modulators
of PDE4D that do not completely inhibit enzymatic activity
were reported to reduce emesis and have therapeutic beneﬁts
of a brain distribution, for such entities as Alzheimer’s
disease, Huntington’s disease, schizophrenia, and depression
[48]. In contrast to PDE4D, selective inhibition of PDE4A
and/or PDE4B in proinﬂammatory and immune cells is
believed to evoke the therapeutically desired eﬀects of these
drugs [49]. Cilomilast has a higher potency for PDE4D
compared to PDE4A and PDE4B, while roﬂumilast is non-
selectiveforthesefourPDE4subtypeswithsimilardegreesof
inhibition [50]. There is no literature about AWD 12-281 s
inhibition of PDE4 subtypes until now. However, whether
hesperetin selectively inhibits the PDE4 subtype also needs
to be further investigated.
In the present results, the PDE4H/PDE4L ratio of hesper-
etin was calculated to be >11, which is greater than that of
AWD 12-281. In addition, hesperetin did not inﬂuence xy-
lazine/ketamine-induced anesthesia. However, Ro 20-1724, a
selective PDE4 inhibitor, reversed the anesthesia. The revers-
ing eﬀect may occur through presynaptic α2-adrenoceptor
inhibition [51], because MK-912, an α2-adrenoceptor antag-
onist, was reported to reverse xylazine/ketamine-induced
anesthesia in rats [52] and trigger vomiting in ferrets [51].
Incontrast,clonidine,anα2-adrenoceptoragonist,prevented
emesis induced by PDE4 inhibitors in ferrets [51]. The
present results also suggest that hesperetin may have few
or no adverse eﬀects, such as nausea, vomiting, and gastric
hypersecretion.
In conclusion, hesperetin exerted anti-inﬂammatory
eﬀects, including suppression of AHR, and reduced expres-
sions of inﬂammatory cells and cytokines in a murine model
of allergic asthma. However, hesperetin did not inﬂuence
xylazine/ketamine-induced anesthesia suggesting that hes-
p e r e t i nh a sf e wo rn oe m e t i ce ﬀects. Thus, the rationales for
ameliorating allergic asthma and COPD by hesperetin are
antiinﬂammation, immunoregulation, and bronchodilation
resulted from PDE4 inhibition and are summarized in
Figure 6.
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